

Viatriis in Europe

We are **approximately 10,000 talented and dedicated individuals** working in **38 countries** across Europe.




One third of our employees work in one of the **13 manufacturing, packaging and R&D sites**

we operate in Europe, across oral solid dose, injectables, active pharmaceutical ingredients (API), complex products and combination product device development. **5 of these sites focus on R&D** – and are located in Switzerland, UK and Ireland



Our European portfolio of more than **700 molecules**



includes globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products.

We produce and supply medicines for patients, across a **broad range of major therapeutic areas** such as,



Cardiovascular



Infectious disease



Oncology



Immunology



CNS and Pain



Diabetes and metabolism



Gastroenterology



Respiratory and allergy



Dermatology



Psychiatry



Urology

We are building partnerships in the space of **non-communicable diseases (NCDs)**.



Viatriis is also a **key player** across the region in **thrombosis**.



Connect with Viatriis:
[Viatriis.com](https://www.viatriis.com) | [LinkedIn](#) | [X](#) | [YouTube](#)
[ViatriisPolicy.eu](https://www.viatriis.com/policy)
[ViatriisEUnewsroom.com](https://www.viatriis.com/eu-newsroom)



Our work in Europe also involves partnering with key stakeholders to **fight antimicrobial resistance (AMR)** – part of the European Commission and United Nation's agenda – with leveraging best practice such as PLATINEA in Sweden

